Knect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Atriva repurposes cancer drug candidates to create universal flu treatment

Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors originally developed as cancer treatments to create a drug that can tackle all known and likely future strains of the influenza virus.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Rainer Lichtenberger – CEO, Atriva Therapeutics

Get the latest news as it happens.